Listar por autor "Poveda, Eva"
Mostrando ítems 1-19 de 19
-
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas, Berta; Grandal, Marta; Pértega-Díaz, Sonia; Cañizares, Angelina; Castro-Iglesias, Ángeles; Mena, Álvaro; Rodríguez-Osorio, Iria; Tabernilla, Andrés; Pedreira, José D.; Poveda, Eva (Oxford University Press, 2015-12-24)[Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ... -
Cancer incidence in persons living with HIV
Meijide, Héctor; Mena, Álvaro; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Poveda, Eva (Oxford University Press para Infectious Diseases Society of America, 2016-11-14) -
Caracterización epidemiológica, clínica y virológica de los nuevos diagnósticos de infección por VHC en Galicia (2014-2015)
Pernas, Berta; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Trigás, M.; Morano, L.; Mariño, A.; Rodríguez-Osorio, Iria; Ocampo, A.; Pereiro, C.; Poveda, Eva (Elsevier, 2016) -
Characterization of chronic HCV infection in Northwest Spain: impact of the treatment strategic plan of the Spanish National Health Service on HCV cure
Grandal, Marta; Pernas, Berta; Mariño, Ana; Álvarez, Hortensia; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Mena, Álvaro; Delgado, Manuel; Pértega-Díaz, Sonia; Poveda, Eva (Wiley, 2017-03-14)[Abstract] The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected ... -
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
Cid-Silva, Purificación; Llibre, Josep M.; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Wiley, 2017-07-16)[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of ... -
Increasing incidence of cancer in persons living with HIV coinfected with HCV: an additional impact of HCV infection?
Mena, Álvaro; Meijide, Héctor; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Pértega-Díaz, Sonia; Rodríguez-Martínez, Guillermo; Pernas, Berta; Baliñas, Josefa; Pedreira, José D.; Poveda, Eva (Elsevier, 2016) -
Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines
Cid-Silva, Purificación; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Mena, Álvaro; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Sage, 2019-01-10)[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count. This study evaluates the immunological and virological ... -
Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV
Mena, Álvaro; Meijide, Héctor; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Poveda, Eva (Wiley, 2017-02-23)[Abstract] Objectives. The aim of this study was to compare liver-related mortality and liver-related hospitalizations for persons living with HIV (PLWH) with and without hepatitis C virus (HCV) exposure, and to estimate ... -
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Pernas, Berta; Grandal, Marta; Tabernilla, Andrés; Cid-Silva, Purificación; Pértega-Díaz, Sonia; Castro-Iglesias, Ángeles; Mena, Álvaro; Margusino-Framiñán, Luis; Pedreira, José D.; Poveda, Eva (Wiley, 2016-06-06)[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ... -
Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers
Mena, Álvaro; Pedreira, José D.; Castro-Iglesias, Ángeles; López, Soledad; Vázquez-Rodríguez, Pilar; Poveda, Eva (Wiley, 2013-12-19)[Abstract] Background and Aim. There are few data of fibrosis development in chronic hepatitis B (CHB) patients classified as inactive carriers. The aim of this study is to determinate the prevalence of significant fibrosis ... -
Molecular characterization of HIV-1 infection in Northwest Spain (2009–2013): investigation of the subtype F outbreak
Paraskevis, Dimitrios; Kostaki, Evangelia; Beloukas, Apostolos; Cañizares, Angelina; Aguilera, Antonio; Rodríguez, Javier; Grandal, Marta; Pernas, Berta; Castro-Iglesias, Ángeles; Mena, Álvaro; Pedreira, José D.; Poveda, Eva (Elsevier, 2014-12-16)[Abstract] Background. HIV-1 subtype B is the predominant one in European regions several, while other subtypes and recombinants are also circulating with high prevalence. A sub-epidemic of subtype F with specific ... -
Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication
Pernas, Berta; Rego-Pérez, Ignacio; Tabernilla, Andrés; Balboa-Barreiro, Vanesa; Relaño, Sara; Grandal, Marta; Crespo, Manuel; Mena, Álvaro; Castro-Iglesias, Ángeles; Blanco García, Francisco J; Poveda, Eva (Oxford, 2017-08-31)[Abstract] Objectives. To evaluate plasma mitochondrial DNA (mtDNA) levels among HIV-infected patients and its potential role as a biomarker of residual viral replication. Methods. HIV-infected patients on follow-up at a ... -
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies
Grandal, Marta; Pernas, Berta; Tabernilla, Andrés; Mariño, Ana; Álvarez, Hortensia; Valcarce, Nieves; Mena, Álvaro; Castro-Iglesias, Ángeles; Pérez, Ana B.; Delgado, Manuel; Poveda, Eva (Wiley, 2018-02-10)[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with ... -
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
Rodríguez-Osorio, Iria; Cid-Silva, Purificación; Morano, Luis; Castro-Iglesias, Ángeles; Suárez, Marta; Delgado, Manuel; Margusino-Framiñán, Luis; Meijide, Héctor; Pernas, Berta; Tabernilla, Andrés; Pedreira, José D.; Mena, Álvaro; Poveda, Eva (Elsevier, 2017-01-18)[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ... -
Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing
Mena, Álvaro; Moldes, Luz; Meijide, Héctor; Cañizares, Angelina; Castro-Iglesias, Ángeles; Delgado, Manuel; Pértega-Díaz, Sonia; Pedreira, José D.; Bou, Germán; Poveda, Eva (PLoS ONE, 2014-12-01) -
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
Cid-Silva, Purificación; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Mena, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Martín-Herranz, Isabel; Míguez-Rey, Martín; Poveda, Eva; Castro-Iglesias, Ángeles (Wiley, 2018-11-02)[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for ... -
Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: impact of hepatitis C co-infection
Meijide, Héctor; Mena, Álvaro; Rodríguez-Osorio, Iria; Pértega-Díaz, Sonia; Castro-Iglesias, Ángeles; Rodríguez-Martínez, Guillermo; Pedreira, José D.; Poveda, Eva (Elsevier, 2017-02-15)[Abstract] Background. New patterns in epidemiological characteristics of people living with HIV infection (PLWH) and the introduction of Highly Active Antiretroviral Therapy (HAART) have changed the profile of hospital ... -
Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years
Pernas, Berta; Mena, Álvaro; Cañizares, Angelina; Grandal, Marta; Castro-Iglesias, Ángeles; Pértega-Díaz, Sonia; Pedreira, José D.; Poveda, Eva (Wiley, 2015-03-16)[Abstract] To describe temporal trend and characteristics of newly HIV-diagnosed patients in a medical care area in Northwest Spain over the last 10 years. All newly diagnosed patients for HIV-infection from 2004 to 2013 ... -
Update on hepatitis C virus resistance to direct-acting antiviral agents
Poveda, Eva; Wyles, David L.; Mena, Álvaro; Pedreira, José D.; Castro-Iglesias, Ángeles; Cachay, Edward (Elsevier, 2014-06-06)[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins. ...